Cargando…

Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis

INTRODUCTION: The management of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) remains challenging in view of the paucity of data and evidence-bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambru, Giorgio, Stubberud, Anker, Rantell, Khadija, Lagrata, Susie, Tronvik, Erling, Matharu, Manjit Singh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892380/
https://www.ncbi.nlm.nih.gov/pubmed/33361408
http://dx.doi.org/10.1136/jnnp-2020-323999
_version_ 1783652836436869120
author Lambru, Giorgio
Stubberud, Anker
Rantell, Khadija
Lagrata, Susie
Tronvik, Erling
Matharu, Manjit Singh
author_facet Lambru, Giorgio
Stubberud, Anker
Rantell, Khadija
Lagrata, Susie
Tronvik, Erling
Matharu, Manjit Singh
author_sort Lambru, Giorgio
collection PubMed
description INTRODUCTION: The management of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) remains challenging in view of the paucity of data and evidence-based treatment recommendations are missing. METHODS: In this single-centre, non-randomised, prospective open-label study, we evaluated and compared the efficacy of oral and parenteral treatments for SUNCT and SUNA in a real-world setting. Additionally, single-arm meta-analyses of the available reports of SUNCT and SUNA treatments were conducted. RESULTS: The study cohort comprised 161 patients. Most patients responded to lamotrigine (56%), followed by oxcarbazepine (46%), duloxetine (30%), carbamazepine (26%), topiramate (25%), pregabalin and gabapentin (10%). Mexiletine and lacosamide were effective in a meaningful proportion of patients but poorly tolerated. Intravenous lidocaine given for 7–10 days led to improvement in 90% of patients, whereas only 27% of patients responded to a greater occipital nerve block. No statistically significant differences in responders were observed between SUNCT and SUNA. In the meta-analysis of the pooled data, topiramate was found to be significantly more effective in SUNCT than SUNA patients. However, a higher proportion of SUNA than SUNCT was considered refractory to medications at the time of the topiramate trial, possibly explaining this isolated difference. CONCLUSIONS: We propose a treatment algorithm for SUNCT and SUNA for clinical practice. The response to sodium channel blockers indicates a therapeutic overlap with trigeminal neuralgia, suggesting that sodium channels dysfunction may be a key pathophysiological hallmark in these disorders. Furthermore, the therapeutic similarities between SUNCT and SUNA further support the hypothesis that these conditions are variants of the same disorder.
format Online
Article
Text
id pubmed-7892380
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-78923802021-03-03 Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis Lambru, Giorgio Stubberud, Anker Rantell, Khadija Lagrata, Susie Tronvik, Erling Matharu, Manjit Singh J Neurol Neurosurg Psychiatry Cranial Neuropathies INTRODUCTION: The management of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) remains challenging in view of the paucity of data and evidence-based treatment recommendations are missing. METHODS: In this single-centre, non-randomised, prospective open-label study, we evaluated and compared the efficacy of oral and parenteral treatments for SUNCT and SUNA in a real-world setting. Additionally, single-arm meta-analyses of the available reports of SUNCT and SUNA treatments were conducted. RESULTS: The study cohort comprised 161 patients. Most patients responded to lamotrigine (56%), followed by oxcarbazepine (46%), duloxetine (30%), carbamazepine (26%), topiramate (25%), pregabalin and gabapentin (10%). Mexiletine and lacosamide were effective in a meaningful proportion of patients but poorly tolerated. Intravenous lidocaine given for 7–10 days led to improvement in 90% of patients, whereas only 27% of patients responded to a greater occipital nerve block. No statistically significant differences in responders were observed between SUNCT and SUNA. In the meta-analysis of the pooled data, topiramate was found to be significantly more effective in SUNCT than SUNA patients. However, a higher proportion of SUNA than SUNCT was considered refractory to medications at the time of the topiramate trial, possibly explaining this isolated difference. CONCLUSIONS: We propose a treatment algorithm for SUNCT and SUNA for clinical practice. The response to sodium channel blockers indicates a therapeutic overlap with trigeminal neuralgia, suggesting that sodium channels dysfunction may be a key pathophysiological hallmark in these disorders. Furthermore, the therapeutic similarities between SUNCT and SUNA further support the hypothesis that these conditions are variants of the same disorder. BMJ Publishing Group 2021-03 2020-12-24 /pmc/articles/PMC7892380/ /pubmed/33361408 http://dx.doi.org/10.1136/jnnp-2020-323999 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Cranial Neuropathies
Lambru, Giorgio
Stubberud, Anker
Rantell, Khadija
Lagrata, Susie
Tronvik, Erling
Matharu, Manjit Singh
Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis
title Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis
title_full Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis
title_fullStr Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis
title_full_unstemmed Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis
title_short Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis
title_sort medical treatment of sunct and suna: a prospective open-label study including single-arm meta-analysis
topic Cranial Neuropathies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892380/
https://www.ncbi.nlm.nih.gov/pubmed/33361408
http://dx.doi.org/10.1136/jnnp-2020-323999
work_keys_str_mv AT lambrugiorgio medicaltreatmentofsunctandsunaaprospectiveopenlabelstudyincludingsinglearmmetaanalysis
AT stubberudanker medicaltreatmentofsunctandsunaaprospectiveopenlabelstudyincludingsinglearmmetaanalysis
AT rantellkhadija medicaltreatmentofsunctandsunaaprospectiveopenlabelstudyincludingsinglearmmetaanalysis
AT lagratasusie medicaltreatmentofsunctandsunaaprospectiveopenlabelstudyincludingsinglearmmetaanalysis
AT tronvikerling medicaltreatmentofsunctandsunaaprospectiveopenlabelstudyincludingsinglearmmetaanalysis
AT matharumanjitsingh medicaltreatmentofsunctandsunaaprospectiveopenlabelstudyincludingsinglearmmetaanalysis